Company profile: HistoGeneX
1.1 - Company Overview
Company description
- Provider of biomarker technologies for translational and clinical research via CAP, CLIA, and BELAC-accredited laboratories. Offers integrated sample management and logistics, biomarker strategy support, oncology assays; flow cytometry, histopathology, genomics, immunoassays; plus CellEngine cytometry analysis software and Olink PEA protein biomarker quantification.
Products and services
- Jining Laboratory Services: Delivers flow cytometry, histopathology, genomics, and immunoassays in a CAP-accredited lab in Jining, China, enabling biomarker analysis for translational and clinical research programs
- Olink PEA Technology: Enables minimal-volume quantification of protein biomarkers from clinical samples with high sensitivity and specificity, supporting robust protein biomarker profiling for research applications
- Oncology Assays: Engineers and deploys assays for exploratory, secondary, and primary endpoints in oncology programs within a CLIA-accredited laboratory framework
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to HistoGeneX
Angle
HQ: United Kingdom
Website
- Description: Provider of liquid biopsy cancer diagnostic products for the capture and harvest of circulating tumor cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Angle company profile →
Zap Surgical
HQ: United States
Website
- Description: Provider of the ZAP-X gyroscopic radiosurgery platform for treating brain tumors, lesions, and head and neck conditions, utilizing a modern linear accelerator that eliminates radioactive source replacements. Offers vault-free design to reduce infrastructure costs, dual independent gantries for >1000 non-coplanar beam angles, tungsten-shielded collimation, and SRS webinars and clinical publications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zap Surgical company profile →
Cullinan Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage oncology therapeutics, including zipalertinib (CLN-081/TAS6417) for NSCLC with EGFR exon 20 insertion mutations in pivotal Phase 2b; CLN-619, an anti-MICA/B antibody tested with a checkpoint inhibitor for advanced solid tumors and multiple myeloma; CLN-049 for relapsed/refractory AML and MDS in Phase 1; and CLN-617, a collagen-binding IL-12/IL-2 fusion for advanced solid tumors, both as monotherapy and in combination with pembrolizumab.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cullinan Therapeutics company profile →
Adze Biotech
HQ: United States
Website
- Description: Provider of pre-clinical oncolytic immunotherapies for cancer, including a chimeric adenoviral platform for systemic delivery of immune-stimulatory transgenes and checkpoint inhibitors to distant and local tumors. Pipeline includes Adze-1.17, which selectively kills tumor cells and releases tumor-derived antigens; Adze-1.17-CD40L for malignant glioma; and Ad657, a recombinant adenovirus with intratumoral and systemic potential across broad malignancies and solid tumor indications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adze Biotech company profile →
Hybrigenics
HQ: France
Website
- Description: Provider of bioinformatics platforms to identify, validate, and inhibit protein interactions to develop cancer therapeutics; a biopharmaceutical company focused on R&D of new targets and therapies against cancer, researching deubiquitinating enzymes (DUBs), and having stopped development of inecalcitol, a vitamin D receptor agonist.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hybrigenics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for HistoGeneX
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to HistoGeneX
2.2 - Growth funds investing in similar companies to HistoGeneX
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for HistoGeneX
4.2 - Public trading comparable groups for HistoGeneX
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →